Marker Therapeutics (NASDAQ:MRKR) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Marker Therapeutics (NASDAQ:MRKR) posted its quarterly earnings results on Monday. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14), Zacks reports. Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%. The firm had revenue of $1.22 million for the quarter, compared to analysts’ expectations of $5.25 million.

Marker Therapeutics Stock Performance

Shares of MRKR traded down $0.09 during trading hours on Tuesday, hitting $1.14. The stock had a trading volume of 119,212 shares, compared to its average volume of 58,826. Marker Therapeutics has a 12 month low of $1.10 and a 12 month high of $5.99. The stock has a fifty day moving average price of $1.60 and a 200 day moving average price of $2.72.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Canaccord Genuity Group initiated coverage on Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 target price for the company. Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th. Finally, WBB Securities reissued a “strong-buy” rating and issued a $12.50 target price on shares of Marker Therapeutics in a research report on Tuesday.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.